-
04
2026
2026.04.24 -
Caliway’s Asia-Pacific Phase 2 Study CBL-0206 Approved by Australia’s HREC to Proceed, Officially Advancing Asia-Pacific Clinical Strategy
Caliway’s Asia-Pacific Phase 2 study of CBL-514 for reduction of abdominal subcutaneous fat, CBL-0206, has received approval from Australia’s HREC to proceed, officially advancing the Company’s Asia-Pacific clinical strategy.
-
04
2026
2026.04.20 -
Caliway Completes U.S. FDA IND Submission for SUPREME-02, the Second Global Pivotal Phase 3 Study of CBL-514. Advancing Dual-Track Global Phase 3 Clinical Development
Caliway has completed the U.S. FDA IND submission for SUPREME-02, the second global multi-national, multi-center pivotal Phase 3 study of CBL-514 for reduction of abdominal subcutaneous fat, progressing on schedule according to the Company’s development plan.
-
04
2026
2026.04.09 -
Caliway's Fat Reduction Drug CBL-514 Phase 2 Clinical Results Accepted by ASJ. CBL-0204's Demonstrated Efficacy and Safety Gain Further Academic Recognition
Clinical results from CBL-0204 Phase 2b, a study of its first-in-class large-area localized fat reduction drug candidate, CBL-514, for subcutaneous fat reduction, have been accepted by the Aesthetic Surgery Journal (ASJ), a globally recognized authority in aesthetic medicine.
-
03
2026
2026.03.31 -
Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at the American Diabetes Association’s 2026 Scientific Sessions
Preclinical research on Caliway’s fat reduction drug candidate CBL-514 in combination with GLP-1R-based weight-loss therapies has been selected for presentation at the American Diabetes Association’s 2026 Scientific Sessions.The presentation will be delivered by W. Timothy Garvey, MD, a globally recognized authority in obesity and metabolic medicine and a scientific advisor to Caliway.
-
03
2026
2026.03.19 -
Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at ECO 2026
Preclinical data on Caliway’s fat reduction drug candidate CBL-514 in combination with GLP-1R-based weight-loss therapies has been selected for oral presentation at the European Congress on Obesity (ECO 2026). The presentation will be delivered by Arya M. Sharma, MD, Caliway’s scientific advisor and a globally recognized authority in obesity medicine, who will discuss CBL-514’s fat-reduction efficacy, differentiated mechanism, and potential scientific value as a complementary approach to current weight-loss therapies.
-
02
2026
2026.02.23 -
Caliway Completes Australian HREC Submission for CBL-0206, Advancing Asia-Pacific Clinical Strategy
CBL-0206 Phase 2 study of Caliway’s first-in-class large-area localized fat reduction drug, CBL-514, has completed Australian HREC submission. The study will be conducted in Taiwan and Australia, with an estimated enrollment of approximately 250 participants. The study aims to expand safety and efficacy data in Asian populations, supporting future NDA filings and Caliway’s global and regional dual-track licensing strategy
